Shots:

• The US FDA’s approval allows Evoke to access its existing $5M line of credit from Eversana for manufacturing and commercialization of Gimoti
• The approval will serve as a novel treatment for gastroparesis with expected commercialization in Q4’20
• Gimoti nasal spray is the novel nasally administered product while Eversana will be responsible for its launch

| Ref: Evoke | Image: Behance